COMMUNIQUÉS West-GlobeNewswire

Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
19/03/2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS Expected to [...]
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
19/03/2026
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable [...]
Diadia Launches AI Platform to Finally Give Women Answers to "Unexplained" Health Problems
19/03/2026
Former Google and Reddit AI scientist builds tool to decode genetic clues standard medicine dismisses as "normal" NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- For women suffering from unexplained infertility, crushing [...]
Causeway Therapeutics Presents Data from Phase 2 Clinical Trial of TenoMiR® for Lateral Epicondylitis at RNA Leaders Europe 2026
19/03/2026
Data Show Statistically Significant Improvements in Pain, Function and Tendon Structure in Appropriately Dosed Patients TenoMiR to Progress to Phase 3 Study for Lateral Epicondylitis, Making it One of the Most Advanced [...]
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
19/03/2026
Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (“TG” or “ [...]
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
19/03/2026
BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited [...]
Evermore Expands Community Health Access in Ohio Through New Partnership with Discount Drug Mart
19/03/2026
BENTONVILLE, Ark., March 19, 2026 (GLOBE NEWSWIRE) -- evermore, the personalized health benefits platform transforming how people access the resources they need to live healthier lives, today announced a new retail [...]
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
19/03/2026
Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthrough Therapy Designation by the FDA [...]
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
19/03/2026
Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March 19, 2026 (GLOBE NEWSWIRE) -- [...]
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
19/03/2026
─ Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathway to [...]
CORRECTION: Lucia Gaitan, M.D., FACOG, First in Miami to Offer Cerene® Endometrial Cryotherapy for Women with Heavy Periods
19/03/2026
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on March 16, 2026 by Channel Medsystems, please note that in the seventh paragraph of the release, the contact details should be 305- [...]
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
19/03/2026
Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR conference on 4 June 2026 [...]
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026
19/03/2026
ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Passing of Genmab A/S’ Annual General Meeting
19/03/2026
Company Announcement At Genmab A/S’ Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approved Discharge was given to the Board of Directors and the Executive Management and the year’s [...]
Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients
19/03/2026
New Counterpart Health whitepaper finds patients whose primary care physicians (PCP) used Counterpart Assistant’s flu-related clinical insight were 1.89 times more likely to receive a flu vaccination — and patients with [...]
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
19/03/2026
SAN DIEGO and TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) today announced that Institutional Shareholder Services (“ISS”), a leading [...]
BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health
19/03/2026
BrainsWay’s investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care BURLINGTON, Mass. and JERUSALEM, March 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. ( [...]
BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
19/03/2026
New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company’s proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 [...]
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
19/03/2026
Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX [...]

Pages